Status:
COMPLETED
Immune Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation
Lead Sponsor:
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Conditions:
Allogeneic Stem Cell Transplantation
GVHD
Eligibility:
All Genders
18+ years
Brief Summary
Graft versus Host disease ( GVHD) is one of the major complications of Allogeneic Stem Cell Transplantation. Acute GVHD develops early ( within 2to 3 months) after transplantation and is the leading c...
Detailed Description
Study Endpoints The primary endpoint of study is detection of circulating cells by flow cytometry before and after Allogeneic Stem Cell Transplantation. We analyze the following cells: Myeloid Dendri...
Eligibility Criteria
Inclusion
- All patients undergoing Allogeneic hemapoietic Stem Cell Transplantation
Exclusion
- Patient not undergoing allogeneic hematopoietic stem cell transplantation
Key Trial Info
Start Date :
August 12 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2018
Estimated Enrollment :
177 Patients enrolled
Trial Details
Trial ID
NCT03233659
Start Date
August 12 2014
End Date
June 1 2018
Last Update
February 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mario Arpinati
Bologna, Italy